Efficacy rate alone not enough to determine overall value of a vaccine Many have highlighted AstraZeneca’s apparent 62% efficacy as a reason for Australia to seek out alternatives, but the candidate has a number of other significant advantages.
How important are COVID vaccine efficacy rates? Experts weigh in on whether greater investment in candidates with a higher efficacy rate would actually provide greater promise of elimination.
Can face masks reduce COVID severity and improve herd immunity? An article in the New England Journal of Medicine hypothesises universal mask-wearing can do both.
Herd immunity for COVID-19 is still a terrible idea Epidemiologist Gideon Meyerowitz-Katz wants to dispel myths about herd immunity and coronavirus without a vaccine.
What are the implications of the first case of COVID reinfection? Genetic sequencing revealed the man in Hong Kong had been infected with two different strains of the coronavirus.
Australian research provides COVID-19 vaccine hope The breakthrough comes after recent studies have suggested long-term immunity from natural infection may not be possible.
More evidence suggests no long-term COVID-19 immunity A new longitudinal study has found coronavirus antibodies diminish rapidly within three months of peaking.
Study raises questions over long-term COVID-19 immunity Antibodies in previously infected patients dropped substantially after two to three months.
Are reports of coronavirus ‘reinfection’ a cause for concern? After more than 100 patients in South Korea reportedly tested positive for COVID-19 a second time, opinions are divided over what this could mean in the long term.
New coronavirus test could be ‘game-changing’ The point-of-care test aims to rapidly determine a person’s immunity to coronavirus and how at-risk they are of contracting severe disease.